RA Capital Management’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $389M | Sell |
11,965,991
-223,158
| -2% | -$7.25M | 6.55% | 2 |
|
|
2025
Q1 | $460M | Buy |
12,189,149
+3,499,959
| +40% | +$132M | 7.69% | 2 |
|
|
2024
Q4 | $711M | Hold |
8,689,190
| – | – | 9.47% | 2 |
|
|
2024
Q3 | $993M | Buy |
8,689,190
+485,436
| +6% | +$55.5M | 11.45% | 2 |
|
|
2024
Q2 | $619M | Hold |
8,203,754
| – | – | 8.19% | 2 |
|
|
2024
Q1 | $560M | Buy |
8,203,754
+312,500
| +4% | +$21.3M | 7.13% | 2 |
|
|
2023
Q4 | $496M | Hold |
7,891,254
| – | – | 7.74% | 3 |
|
|
2023
Q3 | $402M | Hold |
7,891,254
| – | – | 7.92% | 3 |
|
|
2023
Q2 | $394M | Buy |
7,891,254
+600,000
| +8% | +$30M | 7.44% | 3 |
|
|
2023
Q1 | $273M | Buy |
7,291,254
+1,433,795
| +24% | +$53.7M | 6.19% | 2 |
|
|
2022
Q4 | $281M | Buy |
5,857,459
+1,276,256
| +28% | +$61.2M | 5.7% | 2 |
|
|
2022
Q3 | $110M | Hold |
4,581,203
| – | – | 2.35% | 11 |
|
|
2022
Q2 | $99.7M | Hold |
4,581,203
| – | – | 2.66% | 8 |
|
|
2022
Q1 | $111M | Buy |
4,581,203
+340,739
| +8% | +$8.23M | 2.41% | 8 |
|
|
2021
Q4 | $101M | Buy |
4,240,464
+343,599
| +9% | +$8.17M | 1.78% | 14 |
|
|
2021
Q3 | $98.9M | Buy |
3,896,865
+31,057
| +0.8% | +$788K | 1.37% | 24 |
|
|
2021
Q2 | $87M | Hold |
3,865,808
| – | – | 1.4% | 21 |
|
|
2021
Q1 | $76.4M | Buy |
3,865,808
+155,109
| +4% | +$3.06M | 1.15% | 25 |
|
|
2020
Q4 | $98.6M | Sell |
3,710,699
-1,573,119
| -30% | -$41.8M | 1.38% | 24 |
|
|
2020
Q3 | $261M | Sell |
5,283,818
-205,363
| -4% | -$10.1M | 4.77% | 4 |
|
|
2020
Q2 | $174M | Buy |
+5,489,181
| New | +$174M | 3.38% | 6 |
|